July 2012
CardioDx’s Corus CAD Gene Expression Test Performs Equally Well in Both Women and Men for the Assessment of Obstructive Coronary Artery Disease, Study Shows
July 31, 2012
PALO ALTO, Calif. – July 31, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced online publication of a study in the American Heart Journal. The paper, titled “A Gender Specific Blood-Based Gene Expression Score for Assessing Obstructive Coronary Artery Disease in Non-Diabetic Patients: Results of the PREDICT Trial,” reported the performance of the company’s Corus® CAD gene expression test for the assessment of obstructive coronary artery disease (CAD) in men and women presenting with typical and atypical symptoms suggestive of obstructive CAD. The article is in press (available online now) and will appear in the September issue of the journal. “Corus CAD is unique as it is the only gender-specific diagnostic test currently available that accurately risk stratifies patients with obstructive coronary artery disease, accounting for key biological differences between men and women,” said Alexandra Lansky, M.D., Associate Professor of Medicine and Director of the Cardiovascular Research Center at Yale University School of Medicine, who is the lead author of the study. “This study found that commonly used diagnostic approaches, including symptom evaluation and myocardial perfusion imaging, performed less well in women than in men for identifying obstructive coronary artery disease. In contrast, the Corus CAD test performed well in both women and men. Corus CAD offers a reliable diagnostic approach for the assessment of non-diabetic patients, particularly women, with suspected obstructive coronary artery disease.” The study analyzed clinical data from 1,160 patients (58% men and 42% women) enrolled in the PREDICT trial, a prospective, multicenter study designed to develop and validate the Corus CAD test. All patients enrolled in PREDICT had been referred for elective invasive coronary angiography. The patients were classified as cases or controls based on an assessment of obstructive CAD by quantitative coronary angiography (QCA). Data from the QCA analysis was then compared to the blood-based Corus CAD test results to determine test performance. Eric Topol, M.D., Director of the Scripps Translational Science Institute in La Jolla, Calif., was the principal investigator for the trial. The results of the analysis showed that Corus CAD test scores were significantly correlated with obstructive coronary artery disease in both male and female cohorts in PREDICT. The Corus CAD score was significantly and independently associated with obstructive CAD in both men and women, while symptoms of typical angina were significantly associated with obstructive CAD only for men (p<0.001). Each 10-point increase in the Corus CAD score was associated with a twofold increase in the likelihood of obstructive disease in men and women, as well as with an increase in maximum percent stenosis, number of lesions, and total coronary plaque volume. Higher Corus CAD scores were significantly associated with increased likelihood of disease in the overall population and in the male and female subgroups separately (all p=0.001), whereas commonly used myocardial perfusion imaging was not. Women often have non-specific, atypical symptoms of CAD that make the assessment of CAD disease more difficult. Traditional diagnostic methods such as cardiac imaging do not account for gender-specific factors, and the real-world performance of these diagnostic tools is often compromised in women. (1) In addition, many traditional tests involve radiation exposure, and cumulative effective doses of radiation from imaging procedures have been shown to be higher in women than in men. (2) A study published in the March 11, 2010 issue of The New England Journal of Medicine found that in nearly 400,000 patients who underwent elective invasive angiographic procedures, 62 percent were found to have no obstructive coronary artery blockage, (3) despite the fact that the majority of patients (84 percent) had received noninvasive diagnostic tests prior to referral to catheterization. The authors concluded that current modalities for identifying which patients should undergo elective invasive coronary angiography to diagnose obstructive CAD have limitations, and that better methods are needed for patient risk stratification. Typical and atypical presentations of stable chest pain account for up to two percent of all doctor’s office visits each year, or as many as 10,000 patients every day in the U.S. (4,5) “Traditional tests for obstructive coronary artery disease result in many cardiac catheterizations where no disease is found, especially in women,” said Mark Monane, M.D., Chief Medical Officer of CardioDx. “This analysis from the PREDICT trial adds to the clinical evidence demonstrating that the Corus CAD test can accurately and non-invasively help clinicians identify whether or not patients need further diagnostic cardiac evaluation, enabling many patients to avoid unnecessary testing and exposure to radiation risks or imaging agent intolerance.” About Corus CAD With a simple blood draw, Corus CAD can help primary care clinicians and cardiologists exclude obstructive coronary artery disease as the cause of a stable non-diabetic patient's symptoms. It is the first gender-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test is safe and does not expose patients to radiation risks or imaging agent intolerance. The Corus CAD test measures the RNA levels of 23 genes. Because peripheral blood cell RNA levels are altered when obstructive coronary artery disease is present, the Corus CAD score aids clinicians in assessing whether an individual patient’s symptoms may be due to obstructive coronary artery disease. Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinician’s office. Corus CAD is currently available in the United States. Corus CAD has been recognized by The Wall Street Journal’s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME’s Top Ten Medical Breakthroughs. For more information please visit www.cardiodx.com/media-kit/. About CardioDx CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit http://www.cardiodx.com. Media Contact: Nicole Osmer 650.454.0504 nicole@nicoleosmer.com
Continue Reading »
Aditazz Appoints New CEO To Lead Silicon Valley AEC Company
July 25, 2012
SAN BRUNO, Calif., July 25, 2012 /PRNewswire/ -- Aditazz, Inc. today announced that it has appointed veteran executive Dan Pittard as CEO. Pittard takes the reins as the venture-backed company accelerates its drive to transform the practice of architecture, engineering and construction (AEC) for the healthcare industry. Aditazz was founded by three principals with deep expertise in architecture, semiconductor design and computer science, and received Series A funding from Artiman Ventures in late 2011. The company's premise is that the massive construction industry – and particularly complex healthcare construction – is in desperate need of innovation. In response, Aditazz is reinventing the process and technology used to construct healthcare facilities. The company's innovations in design and simulation software as well as manufacturing techniques will result in buildings that are built faster, at less cost, with far greater flexibility, predictability and ultimately better healthcare outcomes – all while maintaining the highest degree of aesthetic and functional elegance. "Aditazz's victory in Kaiser Permanente's 2012 'Small Hospital, Big Idea' competition over more than 100 traditional design firms shows that our approach is ready for real-life applications. It's time for us to scale-up," said Deepak Aatresh, co-founder of Aditazz. "Dan has the right combination of executional expertise and breadth of experience to help Aditazz accelerate growth and get to the next level. We're thrilled to have him on board." Throughout his career, Pittard's has led and grown organizations in a diverse array of industries. He began his career in the construction industry, both in the U.S. and overseas. Later, he was a Partner with McKinsey & Company; a Group Vice President at Amoco Corp., where he oversaw four businesses with $8 billion in revenue; a Senior Vice President and General Manager at PepsiCo; and a Senior Vice President at Gateway Computer. Pittard holds an MBA from Harvard Business School and a B.S. in industrial management from Georgia Tech. Pittard has had a long term interest in the architecture and building industries. He has overseen over $1 billion in construction transactions, and has been an investor in and a board member at several software companies serving the construction industry. "Rarely in my career have I seen an industry as ripe for transformative innovation and a company as well-poised for growth as Aditazz is now," said Mr. Pittard. "This is an exceptional opportunity and I'm honored to be a part of such a creative and energetic team." "Succeeding in a complex undertaking like Aditazz will require an integration mind-set and a very rich and diverse set of experiences at the top leadership level. Dan brings exactly that skill set to our leadership team," said Ajit Singh, lead investor for Artiman Ventures. About Aditazz Aditazz designs and delivers next-generation healthcare facilities by integrating new design, technology and manufacturing techniques. Based in Silicon Valley, the company brings together experts and innovations from the worlds of semiconductor design, computer science, architecture, systems and structural engineering, modular manufacturing and assembly, and healthcare planning and operations. It has created a new generation of tools and technologies that results in dramatic increases in building construction speed, flexibility, predictability, cost-savings and ultimately improved healthcare – all while maintaining the highest degree of aesthetic and functional elegance. Aditazz received funding from Artiman Ventures and is a winner of Kaiser Permanente's 2012 'Small Hospital, Big Idea' design competition. For more information, please visit www.aditazz.com. SOURCE Aditazz, Inc.
Continue Reading »Jamie Lee Curtis Releases Her First Interactive Storybook App With Award-Winning Publisher Auryn, Inc.
July 12, 2012
LOS ANGELES, July 12, 2012 /PRNewswire/ -- Auryn, Inc., the most award-winning digital publisher of interactive children's stories for the iPad and other tablet devices, today announced the launch of its newest title based on Where Do Balloons Go? by New York Times bestselling author and celebrated actress Jamie Lee Curtis. AURYN HD - WHERE DO BALLOONS GO? AN UPLIFTING MYSTERY marks Curtis' debut into digital publishing. Fans of all ages can explore the story like never before as it follows a little boy's imaginative journey when he accidentally lets go of his balloon. AURYN HD - WHERE DO BALLOONS GO? AN UPLIFTING MYSTERY brings Jamie Lee Curtis' gentle and humorous story and Laura Cornell's illustrations to life, enhancing the experience of the original book and adding delightful interactive experiences that encourage children's creativity to soar. AURYN HD - WHERE DO BALLOONS GO? AN UPLIFTING MYSTERY for the iPad is now available on the App Store for $5.99 at http://bit.ly/whball. "I am blown away, excuse the pun. I had no idea how exciting this new wave of publishing could be," said Jamie Lee Curtis. "This is the most cutting-edge and creative venture I have ever been involved with and I'm so pleased that it captures the inherent poignancy of the story of losing a balloon and all the emotions that it brings. I am so very proud to present this to the world." "We are big fans of Jamie Lee Curtis' books and are thrilled that she chose Auryn as her partner in bringing this bestselling children's title to an immersive, interactive format," said Umesh Shukla, founder of Auryn. "We're honored to have another bestselling author and celebrity select Auryn's award-winning creative team and patented technology to launch a ground-breaking -- or in this case, gravity-defying -- storytelling experience." AURYN HD - WHERE DO BALLOONS GO? AN UPLIFTING MYSTERY offers a wide variety of delightful and engaging surprises, allowing readers to: Create an animated balloon movie in the Balloon Theater by building balloon characters (using their own photos), recording dialogue and enacting scenes Create their own balloon animals: Auryn's virtual physics engine gives users a realistic experience of this carnival favorite. After blowing on the iPad to "inflate" virtual balloons, users can then swipe to twist and turn them into fun shapes Have a giggle-fit listening to a funny "helium version" of their voice Send hand-written e-postcards to friends and family as they join the missing balloon on vacation Make over 200 balloons sway to the music at the "Big Balloon Dance" Use a virtual fan to blow the balloons around, connect-the-dots to create new constellations in space and much more AURYN HD - WHERE DO BALLOONS GO? AN UPLIFTING MYSTERY helps build reading skills by offering children the following reading options: Listen to the story, narrated by Jamie Lee Curtis herself, while the text is displayed "Karaoke-style" Touch a word on the page to highlight it and hear it spoken aloud For video of Jamie Lee Curtis describing her inspiration for the story visit http://bit.ly/vidbal and to see her demonstrate the app visit http://bit.ly/vibal2 or visit Auryn's YouTube Channel at http://www.youtube.com/user/AurynInc. About Jamie Lee Curtis Jamie Lee Curtis is the bestselling author of numerous children's books. This fall, Ms. Curtis will publish her 10th book, My Brave Year of Firsts. She has also published My Mommy Hung the Moon, Big Words for Little People, Is There Really A Human Race?, It's Hard To Be Five, I'm Gonna Like Me, Where Do Balloons Go?, Today I Feel Silly and Other Moods That Make My Day, Tell Me Again About The Night I Was Born, and When I Was Little. She is also a film actress with starring roles in such acclaimed films as You Again, Freaky Friday, True Lies, Trading Places and A Fish Called Wanda. In television, Ms. Curtis co-starred opposite Richard Lewis in the sitcom Anything But Love, as well as the title role in TNT's adaptation of Wendy Wasserstein's play, The Heidi Chronicles, and the CBS telefilm, Nicholas' Gift. Ms. Curtis is also an AIDS activist and has a deep and active connection to many children's charities including, Children's Hospital of Pittsburgh and Children's Hospital of Los Angeles. About Auryn, Inc. Founded by Academy award-winning visual effects experts from Hollywood's top movie studios, Auryn Inc. is the most award-winning digital publisher of storybook apps for the iPad, iPhone, Android and other tablet devices. Uniting leading technologists and creative artists, Auryn's patented technology enables the company to produce ground-breaking interactive content for the new emerging tablet medium. Recognized by the Producers Guild of America and Variety magazine as the Digital 25 top innovator in Emerging Media and winner of more app awards than any other digital publisher, Auryn is paving the way in digital publishing and fast-becoming the leader in children's storybook apps. For more on Auryn, visit www.auryn.com and follow on Facebook, Twitter and Pinterest at: www.facebook.com/appsbyauryn, www.twitter.com/AurynApps and http://pinterest.com/appsbyauryn/. Media Contact: Crystal Patriarche, SparkPoint Studio Home of BookSparksPR crystal@BookSparksPR.com 480-650-1688 SOURCE Auryn, Inc. * Reuters is not responsible for the content in this press release.
Continue Reading »Guavus raises $15 million for big data
July 11, 2012
San Francisco Business Times - Wednesday, July 11, 2012, 2:15pm PDT Guavus Inc., a maker of data analysis tools with a big footprint in the telecommunications industry, has raised another $15 million in a Series C round of funding, according to a regulatory filing. The San Mateo company, which has research and development offices in Gurgaon and Ahmedabad, India, has previously filed statements showing $31.5 million raised in several rounds. Investors have included Intel Capital (NASDAQ: INTC), Soffinova Ventures and Artiman Ventures. by Patrick Hoge, Reporter-San Francisco Business Times
Continue Reading »Looxcie article - Viewing the Home Run Derby through the eyes of David Ortiz
July 10, 2012
WEEI.com Blog Network - Full Count - July 10, 2012 - By Rob Bradford KANSAS CITY — David Ortiz sat out Monday’s Home Run Derby, but that doesn’t mean he wasn’t right in the middle of the action. Ortiz wore a Looxcie camera (for a look at the device, click here) on his hat during the contest and was good enough to pass on the video to WEEI.com. The following is the Derby through the eyes of the Red Sox’ designated hitter: http://www.youtube.com/watch?v=RDX-KFqpGfU&feature=player_embedded
Continue Reading »ESG Lab Validates the Benefits of Virident Benchmarks for Measuring Performance of Solid-State Drives
July 10, 2012
MILPITAS, Calif., July 10, 2012—Virident Systems, Inc., a performance leader in flash-based Storage Class Memory (SCM) solutions, today announced that ESG Lab validated benchmarks created by Virident to accurately measure enterprise flash-storage performance. The ESG Lab brief documents the challenges of benchmarking enterprise solid-state drives (SSDs) using current tools and concludes that Virident’s General Public License (GPL) licensed SSDBench benchmark utility is ideally suited to address the challenges associated with predicting the performance of SSDs with real-world application workloads. “If your organization is using or evaluating flash-based solid-state storage, you should download SSDBench and take it for a test drive,” said Brian Garrett, vice president at ESG Lab. “As you consider the benefits of this valuable and relatively expensive new technology, you owe it to yourself and your organization to perform a thorough analysis of your investment.” In the brief, ESG Lab documents the challenges of accurately benchmarking SSDs that are driving the need for the new benchmark methodologies included in SSDBench. The challenges include: Speed: The biggest challenge associated with benchmarking solid-state storage is the dramatic difference in speed compared to traditional disk drives. Conditioning: Flash-based solid-state performance changes over time. To account for this, SSDs need to be conditioned with reads and writes to achieve a steady state. Performance testing of a flash device without conditioning yields results that are higher than users will see in production over time. Wear Leveling: A flash memory cell supports a finite number of writes. Flash controllers address this issue with a set of spare erased cells and algorithms that spread writes as evenly as possible over all the cells in a device. This technology, which is known in the industry as wear leveling, impacts write performance over time. In the worst case, a poor wear-leveling algorithm can lead to a dramatic drop in performance for write-intensive workloads that is referred to in the industry as the “write cliff.” Variability: Performing I/O at the speed of flash introduces a number of performance and tuning challenges for storage architects. Performance of SSDs can vary dramatically over time due to a number of factors, including the queue depth being exercised and the size of I/O requests. Real-world Workloads: Experienced storage professionals recognize the need to test performance with a combination of low-level characterization tests and real-world application workloads. Characterization testing with only reads or only writes is a poor indicator of performance for real-world applications, which tend to be a mix of reads and writes. “Virident created SSDBench because we found our customers didn’t have an industry-accepted means to effectively and accurately measure SSD performance,” said Shridar Subramanian, vice president of product marketing at Virident. “We believe there should be a common benchmarking methodology that models realistic application behavior for SSDs so that customers can appropriately weigh the pros and cons of the multitude of solutions there are in the market. SSDBench is an effective way for customers to determine, prior to their purchase, if an SSD solution they are considering provides adequate performance to ensure a strong ROI.” About SSDBench SSDBench is a freely available General Public License (GPL) benchmarking tool that Virident Systems built for solid-state application workload performance analysis. SSDBench leverages well-known open source benchmarks including FIO, IOZone and INNOSim. Characterization tests run for hours instead of minutes and employ a variety of block sizes and queue depths, with a goal of characterizing performance over time. Application workloads evaluate SSD performance for a variety of real-world applications that benefit from the speed of flash (e.g., analytics, high-frequency trading and OLTP databases). A freely available spreadsheet template automates the graphical presentation of results. About Enterprise Strategy Group Enterprise Strategy Group (ESG) is an integrated, full-service IT analyst and business strategy firm, world-renowned for forward-looking market intelligence, analysis, and consulting services that deliver proven, measurable results. Recognized as one of the world’s top 10 analyst firms by offering a unique blend of capabilities — including world-class market research, hands-on technical product testing, and expert consulting methodologies such as the ESG Strategy Lifecycle — ESG is relied upon by IT professionals, technology vendors, institutional investors, and the media for actionable IT and business intelligence. About Virident Systems Virident Systems enterprise-class Storage Class Memory (SCM) solutions deliver unconditional, consistent performance that supports the most data-intensive content and applications. The inherent advantage associated with this disruptive technology revolutionizes computing by speeding application response time and optimizing datacenter efficiency for new levels of ROI. Virident Systems is backed by strategic investors, Intel®, Cisco® Systems and a leading storage hardware and software solutions provider, as well as venture investors Globespan Capital Partners, Sequoia Capital, and Artiman Ventures. For more information, visit www.virident.com. Virident, Virident FlashMAX, vFAS and the Virident logo are trademarks of Virident Systems. All other products and services listed herein are trademarks of their respective companies. Media Contact: Todd Lane Trainer Communications virident@trainercomm.com 925.271.8213
Continue Reading »InvenSense Sets a New Industry Benchmark with the World’s Smallest Six-Axis Integrated MotionTracking Device
July 10, 2012
SUNNYVALE, California, July 10, 2012 – InvenSense, Inc. (NYSE: INVN), the leading provider of MotionTracking™ devices for consumer electronics, today introduced the MPU- 6500, the company’s next-generation 6-axis MotionTracking device for smartphones, tablets, wearable sensors, and other consumer markets. The MPU-6500, delivered in a 3x3x0.9mm QFN package, is the world’s smallest 6-axis MotionTracking device and incorporates the latest InvenSense design innovations for MEMS 3-axis gyroscopes and accelerometers, enabling dramatically reduced chip size and power consumption, while at the same time improving performance and cost. The new MPU-6500 addresses the market requirements for highperformance applications such as pedestrian navigation, context-aware advertising, and other location-based services, along with supporting the specifications for emerging wearable sensor applications such as remote health monitoring, sports and fitness tracking, and other consumer applications. The MPU-6500 MotionTracking device sets a new benchmark for 6-axis performance with nearly 60% lower power, a 45% smaller package, industry-leading consumer gyroscope performance, and improvements in accelerometer noise, bias, and sensitivity. “We are committed to advancing the Motion Interface market by bringing new innovations with higher performance, smaller package size, lower power consumption, and lower overall solution cost,” said Steve Nasiri, CEO and founder of InvenSense. “InvenSense is the market pioneer and technology leader for MEMS-based Motion Interface solutions and has a long history of delivering ‘world’s first solutions’ and leading-edge technology. We are pleased to deliver another breakthrough product to the market which resets the standard for 6-axis size and performance.” MotionTracking devices like the MPU-6500 are a key component in consumer electronics as they provide an intuitive way for consumers to interact with electronic devices by tracking motion in free space and delivering these motions as input commands. Most consumer electronics manufacturers also prefer “turnkey” MotionTracking devices like the MPU-6500 as these fully integrated devices simplify design-in efforts, accelerate time to market, and enable software developers to easily adopt Motion Interface functionality in their applications. Key benefits of fully integrated MotionTracking devices includes smaller size, lower power consumption, simplified product qualification and inventory management, and guaranteed performance through precise sensor alignment, sensor calibration, and fully optimized MotionFusion™ . The single-chip MPU-6500 integrates a 3-axis accelerometer, a 3-axis gyroscope, and an onboard Digital Motion Processor™ (DMP) in a small 3x3x0.9mm QFN package. The new 6- axis device is the world’s first motion sensor to operate at 1.8 volts and consumes only 6.1mW of power in full operating mode; it incorporates breakthrough gyroscope performance of only ±5dps zero-rate-output and 0.01dps/√Hz of noise; and delivers improved accelerometer specifications including typical 250µg/√Hz of noise, and only 18μA of current in low-power mode. The MPU-6500 software drivers are fully compliant with Google’s latest Android 4.1 Jelly Bean release, and supports new low-power DMP capabilities that offload the host processor to reduce power consumption and simplify application development. The MPU-6500 is sampling now to selected customers with mass production slated for Q4 2012. For additional information please visit our website at www.invensense.com or contact InvenSense Sales at sales@invensense.com. About InvenSense InvenSense Inc. (NYSE: INVN) is the leading provider of MotionTracking™ solutions for consumer electronic devices in the world. The company’s patented Nasiri-Fabrication platform and patent-pending MotionFusion™ technology address the emerging needs of many massmarket consumer applications such as, improved performance, accuracy, and intuitive motion- and gesture-based interfaces. InvenSense technology can be found in consumer electronic markets including smartphones, tablets, gaming devices, optical image stabilization, and remote controls for Smart TVs. InvenSense is headquartered in Sunnyvale, California and has offices in China, Taiwan, Korea, Japan, and Dubai. More information can be found at www.invensense.com.
Continue Reading »Guavus Nominated for 2012 Telecom Council SPIFFY Award
July 10, 2012
San Mateo, CA – July 10, 2012 – Guavus Inc., a leading provider of big data analytics solutions that enable service providers and enterprises to make intelligent and timely decisions, today announced it has been nominated for a 2012 Telecom Council SPIFFY Award in the category of Core Award for Best Fixed Telecom Opportunity. Winners will be announced at a ceremony on September 12 during TC3: Telecom Council Carrier Connections. “Guavus was nominated by over a dozen global operators based on the company’s technology, market opportunity, and the potential long-term, positive impact of Guavus on the telecom industry,” said Liz Kerton, President of the Telecom Council. “The competition was fierce this year with over 200 promising telecom companies being considered for only 5 nominations.” SPIFFY Award nominees for 2012 were selected by the carriers of the Telecom Council’s Service Provider Forum (SPIF) from startups representing the broad range of telecom products and services who presented in Telecom Council meetings from January 2011 through May 2012. Among the promising startups identified to present to the Telecom Council, the nominated companies stand out for their innovation, market opportunity or quantifiable interest among the Council’s 25 global Service Providers including AT&T, British Telecom, DoCoMo, France Telecom/Orange, Swisscom, Verizon, Vodafone and many other fixed and wireless carriers from Europe, Asia, and North and South America listed on the Telecom Council website. “Guavus is honored to be among the nominees for this year’s SPIFFYs,” said Anukool Lakhina, founder and CEO of Guavus. “Recognition from the Telecom Council is testament to Guavus’s track record of success with communications service providers, especially as they employ Guavus’ solutions to increase the value of their business in ways that were previously unfeasible. Our holistic approach has enabled our customers to continuously realize improved efficiencies from big data across both various business functions - marketing, customer care, finance and network operations - as well as multiple business units including wireline, mobility, M2M & digital media environments.” About Guavus Founded in June 2006, Guavus has been built from the ground up to unlock the value of operational, sensor and network generated big data and reduce the economic and technology risk associated with deploying a traditional business intelligence solution. Guavus big data analytics solutions, which are based on pioneering patent-pending technology, include the Guavus Reflex ™ platform integrated with a suite of analytics applications that enable intelligent and timely decision-making. Two of the top three mobile operators and backbone carriers in the United States utilize Guavus big data analytics solutions to control costs, maximize profits and deliver an enhanced end-to-end customer experience. The company is headquartered in San Mateo, CA with research and development offices in Gurgaon and Ahmedabad, India. For more information please visit us on Facebook, LinkedIn or Twitter. Contact: Ty Sheppard Finn Partners for Guavus (310) 488-4495 ty@finnpartners.com
Continue Reading »Guavus Selected as an AlwaysOn Global 250 Winner
July 10, 2012
San Mateo, CA – July 10, 2012 – Guavus Inc., a leading provider of big data analytics solutions that enable service providers and enterprises to make intelligent and timely decisions today announced that it has been chosen by AlwaysOn as one of the AlwaysOn Global 250 winners. Guavus was specially selected by the AlwaysOn editorial team and industry experts spanning the globe based on a set of five criteria: innovation, market potential, commercialization, stakeholder value, and media buzz. Inclusion in the AlwaysOn Global 250 signifies leadership amongst its peers and game-changing approaches and technologies that are likely to disrupt existing markets and entrenched players in the Global Silicon Valley. The Company will be honored at AlwaysOn’s tenth annual Innovation Summit at the Computer History Museum on July 23th, 2012. “We’re honored to be recognized by AlwaysOn for our holistic approach to big data analytics that empower users to make intelligent and timely decisions in a way that is simply not feasible with traditional business intelligence solutions,” said Anukool Lakhina, CEO & Founder, Guavus. “Our cable and telecom service provider customers continue to realize increased value from big data across both various business functions - marketing, customer care, finance, content providers and network operations - as well as multiple business units including wireline, mobility digital media & M2M environments.” “This year’s AlwaysOn Global 250 companies have been shaken up by the recent surge in on-demand and mobile innovation. This year’s crop of robust, innovative applications has launched a complex world of interconnected, sophisticated data being used by a voracious consumer and business userbase. Coupled with a massive smartphone and tablet adoption, the opportunities for this year’s winners are unlimited,” says Tony Perkins, founder and editor of AlwaysOn. “The 2012 AO Global 250 winners are driving the technology market into new, uncharted territory, representing the highest-growth opportunities we’ve seen in the private company marketplace in the history of the Global Silicon Valley.” The AlwaysOn Global 250 winners were selected from among thousands of domestic and international technology companies nominated by investors, bankers, journalists, and industry insiders. The AlwaysOn editorial team conducted a rigorous three-month selection process to finalize the 2012 list. About Guavus Founded in June 2006, Guavus has been built from the ground up to unlock the value of operational, sensor and network generated big data and reduce the economic and technology risk associated with deploying a traditional business intelligence solution. Guavus big data analytics solutions, which are based on pioneering patent-pending technology, include the Guavus Reflex ™ platform integrated with a suite of analytics applications that enable intelligent and timely decision-making. Two of the top three mobile operators and backbone carriers in the United States utilize Guavus big data analytics solutions to control costs, maximize profits and deliver an enhanced end-to-end customer experience. The company is headquartered in San Mateo, CA with research and development offices in Gurgaon and Ahmedabad, India. For more information please visit us on Facebook, LinkedIn or Twitter. Contact: Ty Sheppard Finn Partners for Guavus (310) 488-4495 ty@finnpartners.com
Continue Reading »CardioDx to Present at JMP Securities Healthcare Conference
July 09, 2012
PALO ALTO, Calif. – July 9, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced its participation at the JMP Securities Healthcare Conference to be held July 12-13 in New York. Mark Monane, M.D., the company’s chief medical officer, will provide an overview of CardioDx and of Corus® CAD, the first and only clinically validated gene expression test for obstructive coronary artery disease. The presentation will take place on Thursday, July 12 at 9:30 a.m. ET at the Peninsula Hotel. With a simple blood draw, Corus CAD can help primary care clinicians and cardiologists exclude obstructive coronary artery disease as the cause of a stable non-diabetic patient's symptoms. It is the first gender-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test is safe and does not expose patients to radiation risks or imaging agent intolerance. Corus CAD has been recognized by The Wall Street Journal’s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME’s Top Ten Medical Breakthroughs. About CardioDx CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit http://www.cardiodx.com. Media Contact: Nicole Osmer 650.454.0504 nicole@nicoleosmer.com
Continue Reading »Auryn offers Summer Reads through The Review Wire
July 06, 2012
The Review Wire: Summer Reads by Dena On July-6-2012 -- I was recently introduced to Auryn apps when I had the chance to review the iPad apps Edsel McFarland New Car and The Emperor’s Race. Auryn offers a series of books based on the character Miko. The app is based on Brigitte Weninger and Stephanie Roehe’s book by the same name, and illustrated by Stephanie Roehe. All the stories revolve around Miko, his mother and Miko’s stuffed toy, Mimiki. The Miko Stories: Miko “It was me, Mom!” - Miko wants to see how far his new ball will bounce, but when it bounces right into Mom’s favorite vase, he knows he’s in trouble. What should he do? When Mom comes home, Miko decides that maybe telling the truth won’t be so bad after all. Miko “Mom, Wake up and Play!” - It is the first of the famous Miko series. Miko is wide awake and ready to play, but Mom wants to sleep longer. What can Miko do until her alarm rings? find out how he can pass the time until she’s ready to join him? Miko “No Bath! No Way!” - After Miko’s exciting day, the last thing he wants to do is wash away all the fun things he did! Mom says he doesn’t have to take a bath-but then he will have to endure tickley clothes, sticky ice cream on his face, and sleeping on the hard floor! How far will Miko go to remember his special day? Miko “Double Birthday!” - It’s Miko’s birthday, and he’s as excited as can be. It’s also his friend Mimiki’s birthday, but Miko is the only one who gets any presents. Miko would like to share with him, but it isn’t so easy to find something Mimiki can play with too. How can they have fun with the toys together to make it the best double birthday ever? Miko “Wants a Dog” - Miko wants a pet dog more than anything. His friend Mimiki will pretend to be a dog for a little while, but he won’t go on a leash. Mama says Miko will have to wait until he’s older. He’s so disappointed, until he hears barking from the next door neighbor’s yard, and Miko gets the chance to prove how good he can be with a dog. Miko “Goes on Vacation” - Miko, Mimiki, and their Mom are off to the beach for a vacation. It’s his first trip, full of new sights and surprises. But the beach is full of strangers, and Miko doesn’t want to leave little Mimiki all alone when he goes in the water. Find out how Miko can enjoy swimming so Mimiki won’t be upset. Miko “Where is Mimiki” - Miko is upset. His little friend Mimiki has disappeared! Or could he just be hiding? Miko searches everywhere, but Mimiki is nowhere to be found! Can Miko ever find his friend, and can Mom help make sure that he never gets lost again? Miko “Moves Out” - Whenever Miko wants to play, his mom has a million other things she wants him to do first. Finally, she interrupts his playtime for the last time. Miko is fed up and decides to move out. There are three ways to read the books. “Read to me” – Listen to the narrated story while the text is displayed Karaoke style. After the narration finishes on a page the child can interact with objects till they are ready to move to the next page. “Read myself” – There is no narration but the child can touch a word to hear it being spoken aloud. “Auto Play” – same as “Read to Me” except the page advances automatically once the narration is finished. Useful for those long car rides when you want the child to have a complete book experience. All the Miko apps are available for iPhone, iPad and HD Lite and run $2.99. With the lite version, you are only able to preview a few pages of the book. Stay Connected: Visit Auryn Online to see all the apps they have to offer
Continue Reading »AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
July 02, 2012
LONDON, July 2, 2012 /PRNewswire/ -- AstraZeneca and Cellworks today announced a collaboration supported by the Wellcome Trust to speed the design of novel combination therapies for the treatment of drug-sensitive and resistant tuberculosis. This collaboration will also pave the way for the creation of platforms and approaches to handle Multi Drug Resistant Tuberculosis (MDR-TB), a condition that is reaching epidemic proportions in many developing parts of the world. Current therapies for tuberculosis (TB) are based on creating combinations of three to four drugs and cycling through ad-hoc regimens, which are largely ineffective against MDR-TB. Together, Cellworks and AstraZeneca will pull from a pool of existing anti-infective drugs and attempt to find an effective combination with better efficacy and lower toxicity than the treatment regimens provided today. The traditional process of designing an ideal drug combination is lengthy and expensive as there are several thousand possible combinations and the search space is too large to be handled by conventional wet-lab techniques. Under this collaboration, Cellworks will use its proprietary predictive platform, which it pioneered in oncology and autoimmune disorders, to model drug MDR-TB and rationally identify 'synergistic combinations' that might have the highest efficacy and lowest possible toxic burden compared to all currently available combinations. AstraZeneca will then validate the top ten most effective combinations identified by Cellworks in-vitro in its laboratories, followed by validation using in-vivo models. Dr. Anand Anandkumar, Managing Director, Cellworks Group India said: "Cellworks is honoured to take the lead on this unique drug development project which has the potential to save thousands of lives globally. Its results may also have positive implications in other infectious disease areas where drug resistance is prevalent. We are proud to be working with scientists from AstraZeneca on such a socially valuable project, funded by one of the world's leading science foundations." Dr. Manos Perros, Head of the AstraZeneca Infection Innovative Medicines Unit, said: "AstraZeneca is pleased to join this effort to speed the delivery of improved treatment combinations for TB patients worldwide. Our continued investment in infectious disease research has positioned us to collaborate with organisations like Cellworks who share our passion for medical innovation. AstraZeneca would like to acknowledge and thank the Wellcome Trust for funding this important work. We believe that new medicines and new combination therapies to treat TB will be delivered through a concerted effort from multiple partners rather than one company's lab." Dr. Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "MDR-TB is both a major global healthcare threat and a scientific challenge. Tackling it requires new approaches to drug discovery and we are delighted to be supporting this collaboration which has a strong mix of both innovation and drug development expertise." About Tuberculosis Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. TB is spread from person to person through the air. About one-third of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with disease and cannot transmit the disease. TB occurs in every part of the world. Standard anti-TB drugs have been used for decades, and resistance to the medicines is growing. Disease strains that are resistant to a single anti-TB drug have been documented in every country surveyed. About Cellworks Group, Inc. Cellworks Group Inc. is a biopharmaceutical company designing and developing innovative, but derisked, therapeutic programs. The Cellworks therapeutics pipeline is based on an approach using proprietary validated technology platform which allows emulation of disease physiology computationally and prediction of clinical outcomes. The current disease focus area include Rheumatoid Arthritis, Epithelial based cancers and infectious diseases. For more information please visit: www.cellworksgroup.com. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com About The Wellcome Trust The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk
Continue Reading »